» Articles » PMID: 21693656

BARD1 Expression Predicts Outcome in Colon Cancer

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2011 Jun 23
PMID 21693656
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: BARD1 is a BRCA1-binding partner with tumor suppressive properties. Aberrant splice variants of BARD1 have been detected in various cancers, and it has been postulated that the presence of some splice variants is cancer specific. This is the first study assessing BARD1 expression patterns and correlation with clinical outcome in colon cancer.

Experimental Design: We analyzed colon cancer samples for the occurrence of BARD1 splice variants, characterized novel BARD1 splice variants, and quantified the mRNA expression levels of these isoforms in primary colon cancers and their corresponding normal tissue. We tested the correlation of full-length BARD1 protein expression and clinical outcome in primary colon cancer samples.

Results: In addition to the full-length BARD1 mRNA, we now find 19 distinct BARD1 splice variants in colon cancer. Contrary to previous assumptions, these splice variants also occur in the adjacent normal colon tissue. Although BARD1 splice variants account for a considerable amount of BARD1 mRNA in both cancer and normal colon samples, distinct variants show a cancer-specific regulation pattern. Consistent with its role as tumor suppressor, we further find that the expression of the full-length BARD1 protein predicts outcome in colon cancer and that loss of full-length BARD1 protein is associated with a poor prognosis (P = 0.0002).

Conclusion: Taken together, this is the first report to suggest that BARD1 regulation is an important pathway in colon cancer and that the BARD1 full-length protein may be a useful marker to improve risk stratification in colon cancer patients.

Citing Articles

BARD1 deletion in a patient with suspected hereditary colorectal cancer.

Takaiso N, Imoto I, Yoshimura A, Ouchi A, Komori K, Iwata H Hum Genome Var. 2024; 11(1):11.

PMID: 38485918 PMC: 10940602. DOI: 10.1038/s41439-024-00267-y.


Isoform alterations in the ubiquitination machinery impacting gastrointestinal malignancies.

Kasturirangan S, Nancarrow D, Shah A, Lagisetty K, Lawrence T, Beer D Cell Death Dis. 2024; 15(3):194.

PMID: 38453895 PMC: 10920915. DOI: 10.1038/s41419-024-06575-z.


Zooming into the structure-function of RING finger proteins for anti-cancer therapeutic applications.

George M, Masamba P, Iwalokun B, Kappo A Am J Cancer Res. 2023; 13(7):2773-2789.

PMID: 37559981 PMC: 10408477.


Germline heterozygous exons 8-11 pathogenic BARD1 gene deletion reported for the first time in a family with suspicion of a hereditary colorectal cancer syndrome: more than an incidental finding?.

Carrera S, Rodriguez-Martinez A, Garin I, Sarasola E, Martinez C, Maortua H Hered Cancer Clin Pract. 2023; 21(1):2.

PMID: 36709314 PMC: 9883939. DOI: 10.1186/s13053-023-00246-4.


BARD1 mystery: tumor suppressors are cancer susceptibility genes.

Hawsawi Y, Shams A, Theyab A, Abdali W, Hussien N, Alatwi H BMC Cancer. 2022; 22(1):599.

PMID: 35650591 PMC: 9161512. DOI: 10.1186/s12885-022-09567-4.


References
1.
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

2.
Rozen S, Skaletsky H . Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 1999; 132:365-86. DOI: 10.1385/1-59259-192-2:365. View

3.
Owzar K . Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials. J Clin Oncol. 2008; 26(9):1400-1. DOI: 10.1200/JCO.2007.14.7306. View

4.
Feki A, Jefford C, Berardi P, Wu J, Cartier L, Krause K . BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinase. Oncogene. 2005; 24(23):3726-36. DOI: 10.1038/sj.onc.1208491. View

5.
Carethers J, Smith E, Behling C, Nguyen L, Tajima A, Doctolero R . Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology. 2004; 126(2):394-401. DOI: 10.1053/j.gastro.2003.12.023. View